1) Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017;15:276-83.
3) McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf 2016;14:144-67.
4) Yamaguchi T. Inflammatory response in dry eye. Invest Ophthalmol Vis Sci 2018;59:DES192-9.
5) Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42.
6) Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005;24:80-5.
9) Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 2016;26:287-96.
11) Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol 2014;66:531-41.
12) Lallemand F, Schmitt M, Bourges JL, et al. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm 2017;117:14-28.
14) Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea 2013;32:345-54.
15) Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003;56:307-18.
16) de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol 2019;13:1115-22.
17) Labetoulle M, Leonardi A, Amrane M, et al. Persistence of efficacy of 0.1% cyclosporin a cationic emulsion in subjects with severe keratitis due to dry eye disease: a nonrandomized, open-label extension of the SANSIKA study. Clin Ther 2018;40:1894-906.
18) Van Buskirk EM. The compliance factor. Am J Ophthalmol 1986;101:609-10.
21) Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56.
23) Park JY, Kim BG, Kim JS, Hwang JH. Matrix metalloproteinase 9 point-of-care immunoassay result predicts response to topical cyclosporine treatment in dry eye disease. Transl Vis Sci Technol 2018;7:31.
24) Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J 1995;21:221-32.
25) Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry. Am J Ophthalmol 2010;149:405-15.
26) Epitropoulos AT, Therattil A, Periman LM, Rosenberg ED. Improving tolerance and compliance with topical immunomodulators using micro-emulsion lipid layer artificial tears. Clin Ophthalmol 2020;14:1921-9.
27) Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008;126:1046-50.
28) Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9.
30) Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004;78:409-16.
31) Roszkowska AM, Colosi P, Ferreri FM, Galasso S. Age-related modifications of corneal sensitivity. Ophthalmologica 2004;218:350-5.
32) Yang S, Lee HJ, Kim DY, et al. The use of conjunctival staining to measure ocular surface inflammation in patients with dry eye. Cornea 2019;38:698-705.
34) Lilja J, Lindegren H, Forsby A. Surfactant-induced TRPV1 activity--a novel mechanism for eye irritation? Toxicol Sci 2007;99:174-80.
36) Galor A, Moein HR, Lee C, et al. Neuropathic pain and dry eye. Ocul Surf 2018;16:31-44.